Krege S - Search Results

1

Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer.

Galsky MD, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Bamias A. Galsky MD, et al. Among authors: krege s. Urol Oncol. 2014 Jan;32(1):30.e15-21. doi: 10.1016/j.urolonc.2012.11.001. Epub 2013 Feb 18. Urol Oncol. 2014. PMID: 23428534

2

The impact of gender on outcomes in patients with metastatic urothelial carcinoma.

Haines L, Bamias A, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Galsky MD. Haines L, et al. Among authors: krege s. Clin Genitourin Cancer. 2013 Sep;11(3):346-52. doi: 10.1016/j.clgc.2013.04.010. Epub 2013 May 11. Clin Genitourin Cancer. 2013. PMID: 23673281

3

Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.

Galsky MD, Krege S, Lin CC, Hahn N, Ecke T, Moshier E, Sonpavde G, Godbold J, Oh WK, Bamias A. Galsky MD, et al. Among authors: krege s. Cancer. 2013 Aug 15;119(16):3020-6. doi: 10.1002/cncr.28145. Epub 2013 May 29. Cancer. 2013. PMID: 23720197 Free article.

4

Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.

Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Godbold J, Oh WK, Bamias A. Galsky MD, et al. Among authors: krege s. Cancer. 2013 Aug 15;119(16):3012-9. doi: 10.1002/cncr.28146. Epub 2013 May 29. Cancer. 2013. PMID: 23720216 Free article.

5

Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.

Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Pond G, Godbold J, Oh WK, Bamias A. Galsky MD, et al. Among authors: krege s. Urol Oncol. 2014 Jan;32(1):48.e1-8. doi: 10.1016/j.urolonc.2013.07.001. Epub 2013 Sep 18. Urol Oncol. 2014. PMID: 24055428

6

Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma.

Leiter A, Doucette J, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Bamias A, Oh WK, Galsky MD. Leiter A, et al. Among authors: krege s. Bladder Cancer. 2016 Jul 27;2(3):341-349. doi: 10.3233/BLC-160047. Bladder Cancer. 2016. PMID: 27500201 Free PMC article.

7

[Chemotherapy of advanced urological tumors].

Krege S. Krege S. Onkologie. 2003 Oct;26 Suppl 4:13-7. doi: 10.1159/000074740. Onkologie. 2003. PMID: 14605451 Review. German.

8

[Chemotherapy of testicular cancer].

Krege S, Hartmann JT, Rübben H. Krege S, et al. Urologe A. 2006 May;45(5):600-4. doi: 10.1007/s00120-006-1047-1. Urologe A. 2006. PMID: 16612645 Review. German.

9

Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study.

Krege S, Rembrink V, Börgermann C, Otto T, Rübben H. Krege S, et al. J Urol. 2001 Jan;165(1):67-71. doi: 10.1097/00005392-200101000-00017. J Urol. 2001. PMID: 11125366 Clinical Trial.

10

Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1): a clinical Phase II study.

Otto T, Bex A, Krege S, Walz PH, Rübben H. Otto T, et al. Among authors: krege s. Cancer. 1997 Aug 1;80(3):465-70. doi: 10.1002/(sici)1097-0142(19970801)80:3<465::aid-cncr14>3.0.co;2-v. Cancer. 1997. PMID: 9241080 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

180 results

Search Page

Filters